Challenge
The high-profile Zika virus outbreak in 2016 proved that the disease causes serious birth defects in humans and highlighted an immediate need for an approved vaccine. Based on our successful track record in vaccine testing, Battelle was chosen to evaluate the systemic toxicity, local tolerability and immunogenicity of a Biopharma company’s purified recombinant protein vaccine candidate. The vaccine was under a clinical hold order from the FDA, which prevented it from going to clinical study in humans.
The Solution
Battelle performed GLP toxicology and immunogenicity testing and demonstrated that the vaccine generated a systemic immune response without systemic or local toxicity in preclinical models.
Contact us today for a free, no-obligation assessment. Contact Us.
Connect with an expert
opens in a new page
The Outcome
The FDA accepted Battelle's data, removed the clinical hold and allowed progression of the vaccine candidate to clinical trials. The vaccine candidate was granted fast-track designation by the Food and Drug Administration (FDA).
We help deliver life-saving diagnostic and therapeutic solutions for victims of chemical and biological warfare or pandemic diseases.
Explore Therapeutics, Prophylaxis and Diagnostics
opens in a new page
Case Studies
Technology Commercialization and Licensing
With over 90 years of research and development experience, Battelle supports all areas of industry with intellectual property licensing focused on bringing our cross-disciplinary expertise to meet our clients' most difficult challenges.
